

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-69. (Canceled)

70. (New) A method for making a cell that produces a therapeutically hypermutated immunogen comprising the steps of:

introducing into a cell that expresses a gene encoding a preselected immunogen *in vitro* a polynucleotide comprising a dominant negative allele of a mismatch repair gene, wherein said dominant negative allele is a truncation mutant of a PMS2,

selecting cells that comprise a mutation in said gene encoding said preselected immunogen.

71. (New) The method of claim 70 further comprising a step of expressing a polynucleotide sequence of said mutated gene encoding said preselected immunogen in a genetically stable cell.

72. (New) The method of claim 70 or 71 wherein said introduction of said polynucleotide is in the presence of at least one DNA mutagen.

73. (New) The method of claim 70 or 71 wherein the *PMS2* mismatch repair gene is human *PMS2*.

74. (New) The method of claim 73 wherein the allele comprises a truncation mutation at codon 134.

75. (New) The method of claim 74 wherein the truncation mutation is a thymidine at nucleotide 424 of wild-type PMS2.

76. (New) The method of claim 70 or 71 wherein said step of selecting cells is based on a determination that the polynucleotide encoding said preselected immunogen comprises a mutation as compared to the polynucleotide of a parental cell prior to introduction of said dominant negative allele of a *PMS2* mismatch repair gene

77. (New) A homogeneous culture of cells produced by the method of claim 70 or 71.